Literature DB >> 7977068

Indications for low-density lipoprotein apheresis.

B R Gordon1, E Stein, P Jones, D R Illingworth.   

Abstract

Low-density lipoprotein (LDL) apheresis offers an additional approach to lipid lowering in patients with severe hypercholesterolemia who fail to respond adequately to diet and drug therapy. Well-defined criteria for patient selection have yet to be established for LDL apheresis. This study proposes guidelines based on whether coronary artery disease (CAD) is present and on the degree of LDL cholesterol elevation after treatment with diet and maximal drug therapy. It is reasonable to consider LDL apheresis therapy for: (1) patients with CAD and LDL cholesterol levels > 190 mg/dl; (2) patients without CAD, but at high risk for disease due to an LDL cholesterol level > 250 mg/dl, a first-degree relative with premature CAD, and the presence of > or = 1 additional risk factor. In addition, LDL apheresis is recommended for the management of all patients with homozygous familial hypercholesterolemia due to the very high risk of CAD and the poor response to usual lipid-lowering treatments.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977068     DOI: 10.1016/0002-9149(94)90461-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Atheroembolism.

Authors:  John S. Smyth; John E. Scoble
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-06

Review 2.  Current Treatment of Familial Hypercholesterolaemia.

Authors:  Cameron T Lambert; Pratik Sandesara; Ijeoma Isiadinso; Maria Carolina Gongora; Danny Eapen; Neal Bhatia; Jefferson T Baer; Laurence Sperling
Journal:  Eur Cardiol       Date:  2014-12

3.  Preregistration house officers in general practice.

Authors:  J Wilton
Journal:  BMJ       Date:  1995-02-11

Review 4.  Gene therapy for dyslipidemia: clinical prospects.

Authors:  D J Rader; U J Tietge
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.113

5.  Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.

Authors:  Puja K Mehta; Jefferson Baer; Christine Nell; Laurence S Sperling
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

6.  Gene therapy for lipid disorders.

Authors:  Daniel J Rader
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

7.  Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles.

Authors:  Jiong-Wei Wang; Ya-Nan Zhang; Siu Kwan Sze; Sander M van de Weg; Flora Vernooij; Arjan H Schoneveld; Sock-Hwee Tan; Henri H Versteeg; Leo Timmers; Carolyn S P Lam; Dominique P V de Kleijn
Journal:  Int J Mol Sci       Date:  2017-12-29       Impact factor: 5.923

8.  Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low-density lipoprotein apheresis for 16 years without percutaneous coronary intervention.

Authors:  Takanori Yasu; Masahiro Shimoyama; Hiroshi Wada; Tomohiro Iwakura; Shigeru Toyoda; Atsuhiko Kawabe; Takushi Sugiyama
Journal:  Clin Case Rep       Date:  2019-07-16

9.  Lateral ST-elevation myocardial infarction after donation of COVID-19 convalescent plasma in a naïve donor.

Authors:  Pirbhat Shams; Fateh Ali Tipoo
Journal:  BMJ Case Rep       Date:  2021-03-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.